DarioHealth Announces CFO Transition
DarioHealth Corp. (NASDAQ: DRIO) announced a significant leadership transition as CFO Zvi Ben-David will retire effective May 15, 2025. Chen Franco-Yehuda has been appointed as the new Chief Financial Officer, Treasurer, and Secretary.
Ben-David will remain with the company through June 2025 and continue in an advisory role thereafter. Franco-Yehuda joins Dario with extensive experience in healthcare and life sciences, most recently serving as CFO at Pluri Inc. Her achievements include securing capital through public and private fundraising, executing non-dilutive funding agreements, and driving M&A activity. She was awarded the Israeli CFO Excellence Award in January 2025.
Under Ben-David's tenure, DarioHealth transformed from a single-condition solution provider into a comprehensive multi-condition digital health platform, expanding across diabetes, hypertension, mental health, weight management, and musculoskeletal care.
DarioHealth Corp. (NASDAQ: DRIO) ha annunciato un importante cambiamento nella leadership: il CFO Zvi Ben-David andrà in pensione a partire dal 15 maggio 2025. Chen Franco-Yehuda è stata nominata nuovo Chief Financial Officer, Tesoriere e Segretario.
Ben-David resterà in azienda fino a giugno 2025 e continuerà a svolgere un ruolo di consulenza successivamente. Franco-Yehuda arriva in Dario con una vasta esperienza nel settore sanitario e delle scienze della vita, avendo ricoperto recentemente il ruolo di CFO presso Pluri Inc. Tra i suoi successi figurano la raccolta di capitali attraverso finanziamenti pubblici e privati, la gestione di accordi di finanziamento non diluitivi e la promozione di attività di fusioni e acquisizioni. Nel gennaio 2025 ha ricevuto il premio Israeli CFO Excellence Award.
Durante la gestione di Ben-David, DarioHealth si è trasformata da fornitore di soluzioni per una singola patologia a una piattaforma digitale sanitaria multi-condizione, ampliandosi nei settori del diabete, ipertensione, salute mentale, gestione del peso e cura muscoloscheletrica.
DarioHealth Corp. (NASDAQ: DRIO) anunció una importante transición en su liderazgo: el CFO Zvi Ben-David se retirará a partir del 15 de mayo de 2025. Chen Franco-Yehuda ha sido nombrada nueva Directora Financiera, Tesorera y Secretaria.
Ben-David permanecerá en la empresa hasta junio de 2025 y continuará en un rol asesor posteriormente. Franco-Yehuda llega a Dario con amplia experiencia en el sector salud y ciencias de la vida, habiendo sido CFO recientemente en Pluri Inc. Entre sus logros destacan la obtención de capital mediante financiamiento público y privado, la ejecución de acuerdos de financiamiento no dilutivos y la promoción de actividades de fusiones y adquisiciones. En enero de 2025 recibió el premio Israeli CFO Excellence Award.
Bajo la dirección de Ben-David, DarioHealth se transformó de un proveedor de soluciones para una sola condición a una plataforma digital de salud multipatología, expandiéndose en diabetes, hipertensión, salud mental, control de peso y cuidado musculoesquelético.
DarioHealth Corp. (NASDAQ: DRIO)는 중대한 리더십 변화를 발표했습니다. CFO Zvi Ben-David는 2025년 5월 15일부로 은퇴할 예정입니다. Chen Franco-Yehuda가 새로운 최고재무책임자(CFO), 재무담당, 그리고 비서로 임명되었습니다.
Ben-David는 2025년 6월까지 회사에 남아 있으며 이후 자문 역할을 계속할 예정입니다. Franco-Yehuda는 최근 Pluri Inc.에서 CFO로 근무하는 등 의료 및 생명과학 분야에서 풍부한 경험을 가지고 Dario에 합류했습니다. 그녀의 주요 성과로는 공개 및 비공개 자금 조달, 비희석성 자금 계약 실행, 인수합병(M&A) 활동 주도 등이 있으며, 2025년 1월 이스라엘 CFO 우수상(Israeli CFO Excellence Award)을 수상했습니다.
Ben-David 재임 기간 동안 DarioHealth는 단일 질환 솔루션 제공자에서 당뇨병, 고혈압, 정신 건강, 체중 관리, 근골격계 치료 등 다양한 질환을 포괄하는 종합 디지털 헬스 플랫폼으로 탈바꿈했습니다.
DarioHealth Corp. (NASDAQ: DRIO) a annoncé une transition majeure dans sa direction : le CFO Zvi Ben-David prendra sa retraite à compter du 15 mai 2025. Chen Franco-Yehuda a été nommée nouvelle Directrice Financière, Trésorière et Secrétaire.
Ben-David restera au sein de l'entreprise jusqu'en juin 2025 et continuera ensuite à jouer un rôle consultatif. Franco-Yehuda rejoint Dario avec une vaste expérience dans le secteur de la santé et des sciences de la vie, ayant récemment occupé le poste de CFO chez Pluri Inc. Parmi ses réalisations figurent la levée de fonds publics et privés, la mise en œuvre d'accords de financement non dilutifs, ainsi que la conduite d'activités de fusions et acquisitions. Elle a reçu le prix Israeli CFO Excellence Award en janvier 2025.
Sous la direction de Ben-David, DarioHealth est passée d'un fournisseur de solutions pour une seule pathologie à une plateforme digitale de santé multi-pathologies, s'étendant au diabète, à l'hypertension, à la santé mentale, à la gestion du poids et aux soins musculo-squelettiques.
DarioHealth Corp. (NASDAQ: DRIO) gab einen bedeutenden Führungswechsel bekannt: CFO Zvi Ben-David wird zum 15. Mai 2025 in den Ruhestand treten. Chen Franco-Yehuda wurde zur neuen Chief Financial Officer, Schatzmeisterin und Sekretärin ernannt.
Ben-David wird dem Unternehmen bis Juni 2025 erhalten bleiben und anschließend eine beratende Funktion übernehmen. Franco-Yehuda bringt umfangreiche Erfahrung im Gesundheits- und Life-Sciences-Bereich mit und war zuletzt CFO bei Pluri Inc. Zu ihren Erfolgen zählen die Kapitalbeschaffung durch öffentliche und private Finanzierungen, die Umsetzung nicht verwässernder Finanzierungsvereinbarungen sowie die Steuerung von M&A-Aktivitäten. Im Januar 2025 wurde sie mit dem Israeli CFO Excellence Award ausgezeichnet.
Unter Ben-Davids Führung wandelte sich DarioHealth von einem Anbieter für Einzelkrankheiten zu einer umfassenden digitalen Gesundheitsplattform für mehrere Krankheitsbilder, die Diabetes, Bluthochdruck, psychische Gesundheit, Gewichtsmanagement und muskuloskelettale Versorgung abdeckt.
- Incoming CFO brings strong healthcare finance experience and proven track record in capital raising
- Smooth leadership transition planned with retiring CFO staying on as advisor
- Company has successfully expanded from single to multi-condition digital health platform
- Loss of experienced CFO who led company through significant transformation period
The Company has appointed Chen Franco-Yehuda as its new Chief Financial Officer, Treasurer, and Secretary, and will assume the role upon Mr. Ben-David's retirement on May 15, 2025. To ensure a smooth transition, Mr. Ben-David will remain with the Company until the end of June, after which he will move to assist the Company in an advisory capacity.
"It has been an incredible journey at DarioHealth, and I am proud of what we have accomplished," said Mr. Ben-David. "I am confident in Chen's ability to lead the Company's financial strategy and contribute to its continued growth."
Mrs. Franco-Yehuda brings extensive financial leadership experience, with a strong background in corporate finance, capital markets, and strategic growth initiatives. She has held senior financial leadership roles across publicly traded companies in the healthcare and life sciences sectors. Combining deep knowledge of healthcare business models with a sharp understanding of capital markets, her experience uniquely positions her to lead Dario's financial organization through its next phase of growth and expansion.
Prior to joining Dario, she most recently served as Chief Financial Officer, Treasurer, and Secretary at Pluri Inc. (Nasdaq, TASE: PLUR), a global biotech company, where she led financial strategy, investor relations, legal affairs, and significant cross-border transactions. She played an instrumental role in securing substantial capital through multiple public and private fundraising rounds, executing non-dilutive funding agreements and driving merger and acquisition activity. In recognition of her accomplishments, she was awarded the Israeli CFO Excellence Award in January 2025.
Chen's early career started as Audit/Assurance Manager at PwC. She is a licensed CPA in
"On behalf of the Board and the entire team at DarioHealth, I would like to express our gratitude to Zvi for his dedication and contributions to the Company," said Erez Raphael, CEO of DarioHealth. "During his tenure, Zvi played a key role in the Company's transformation from a single-condition solution provider into one of the most comprehensive multi-condition digital health platforms in the industry. His financial stewardship supported our strategic expansion across diabetes, hypertension, mental health, weight management, and musculoskeletal care, helping to position Dario as a leader in digital health. We look forward to welcoming Chen and leveraging her expertise as we continue to drive innovation and growth."
About DarioHealth Corp.
DarioHealth Corp. (Nasdaq: DRIO) is a leading digital health company revolutionizing how people with chronic conditions manage their health through a user-centric, multi-chronic condition digital therapeutics platform. Dario's platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health.
Dario provides its highly user-rated solutions globally to health plans and other payers, self-insured employers, providers of care, and consumers. To learn more about Dario and its digital health solutions, or for more information, visit http://dariohealth.com.
Cautionary Note Regarding Forward-Looking Statements
This news release and the statements of representatives and partners of DarioHealth Corp. related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. . Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the
DarioHealth Corporate Contact
Mary Mooney
VP Marketing
mary@dariohealth.com
+1-312-593-4280
DarioHealth Investor Relations Contact
Kat Parrella
Investor Relations Manager
kat@dariohealth.com
+315-378-6922
Logo - https://mma.prnewswire.com/media/1920436/DarioHealth_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/dariohealth-announces-cfo-transition-302433262.html
SOURCE DarioHealth Corp.
FAQ
When will Chen Franco-Yehuda start as DarioHealth's (DRIO) new CFO?
What experience does DarioHealth's (DRIO) new CFO bring to the company?
How has DarioHealth (DRIO) expanded its services under the departing CFO's tenure?
What transition arrangements are in place for DarioHealth's (DRIO) CFO change?
